Symbols / RNAZ Stock $6.11 -1.10% TransCode Therapeutics, Inc.
RNAZ (Stock) Chart
Stock Fundamentals
|
|
|
|
|
|
About
Official websiteTransCode Therapeutics, Inc., a clinical-stage company, develops immuno-oncology and RNA therapeutics for the treatment of high risk and advanced cancers. The company's therapeutic candidate comprises SEVIPROTIMUT-L for the adjuvant treatment of patients with Stages IIB and IIC melanoma that has completed Phase 2 clinical trial; TTX-MC138 that targets microRNA-10b, a master regulator of metastatic cell viability in various cancers comprising breast, pancreatic, ovarian, colon cancer, glioblastomas, and others that has completed Phase 1 clinical trial. Its preclinical programs include TTX-siPDL1, an siRNA-based modulator of programmed death-ligand 1 and two indication agnostic programs; TTX-RIGA, an RNA- based agonist of the retinoic acid-inducible gene I targeting activation of innate immunity in the tumor microenvironment; and TTX-siMYC, an siRNA-based MYC inhibitor. The company is also developing oncolytic virus therapy. TransCode Therapeutics, Inc. has strategic collaboration agreement with The University of Texas M. D. Anderson Cancer Center. The company was incorporated in 2016 and is based in Boston, Massachusetts.
Ratings
Current target
$6.11
Low
—
High
—
Mean
—
Latest analyst rating changes
| Date | Action | Analyst | Rating Change | Price Target |
|---|---|---|---|---|
| 2025-04-16 | main | HC Wainwright & Co. | Buy → Buy | $10 |
| 2025-03-13 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-02-07 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2025-02-06 | reit | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-12-18 | main | HC Wainwright & Co. | Buy → Buy | $20 |
| 2024-11-15 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-10-24 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-09-06 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-08-15 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-05-29 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-05-16 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-04-16 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
| 2024-04-03 | reit | HC Wainwright & Co. | Buy → Buy | $3 |
- [EFFECT] Transcode Therapeutics, Inc. SEC Filing - Stock Titan Wed, 20 May 2026 10
- RNAZ Stock Price, Quote & Chart | TRANSCODE THERAPEUTICS INC (NASDAQ:RNAZ) - ChartMill Fri, 15 May 2026 07
- TransCode Secures Exclusive, Worldwide, Fully Paid-Up Royalty-Free License to Develop and Commercialize a Next-Generation Oncolytic Immunotherapy Platform in an All-Stock Transaction Underscoring the Company's Dedication to Improving the Lives of - PR Newswire ue, 03 Mar 2026 08
- TransCode Therapeutics stock soars after promising glioblastoma study - Investing.com ue, 06 Jan 2026 08
- [10-Q] Transcode Therapeutics, Inc. Quarterly Earnings Report - Stock Titan Fri, 15 May 2026 20
- TransCode Therapeutics (RNAZ) announces the acquisition of Polynoma and a $25 Million strategic financing by a subsidiary of CK Life Sciences to form a first-in-class unique immuno-oncology and metastatic prevention oncology company - PR Newswire Wed, 08 Oct 2025 07
- TransCode Therapeutics (RNAZ) Stock: Volatility Overview (-4.45%) 2026-04-22 - Social Buzz - Xã Thanh Hà Wed, 22 Apr 2026 15
- TransCode Therapeutics’ TTX-MC138 Excites Market with Promising Glioblastoma Data - StocksToTrade hu, 05 Feb 2026 08
- RNAZ (TransCode Therapeutics Inc.) posts far wider than expected Q4 2024 loss, shares notch small gain in today’s trading. - Net Debt/EBITDA - Cổng thông tin điện tử tỉnh Lào Cai Wed, 22 Apr 2026 20
- symbol__ Stock Quote Price and Forecast - CNN hu, 18 Jan 2024 20
- TransCode Therapeutics Secures New Financing to Extend Runway - TipRanks ue, 07 Apr 2026 07
- TransCode Therapeutics (NASDAQ: RNAZ) registers 15.96M resale shares by selling holders - Stock Titan hu, 30 Apr 2026 07
- TransCode Therapeutics (RNAZ) Stock Dual Listing (Smart Money Flows) 2026-04-15 - Verified Signals - Cổng thông tin điện tử tỉnh Lào Cai Wed, 15 Apr 2026 07
- Colorectal cancer study to test RNA drug TTX-MC138 after standard treatment - Stock Titan hu, 05 Feb 2026 08
- TransCode Therapeutics (NASDAQ: RNAZ) sets up 1.53M-share SEPA resale - Stock Titan hu, 30 Apr 2026 07
Insider Transactions
No recent insider transactions.
Financials
Statement View
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Total Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Revenue |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Operating Expense |
|
17.92
+18.36%
|
15.14
-18.16%
|
18.50
+5.37%
|
17.55
|
| Research And Development |
|
13.42
+38.28%
|
9.71
-20.85%
|
12.26
+19.85%
|
10.23
|
| Selling General And Administration |
|
5.77
-3.08%
|
5.95
-16.78%
|
7.15
-14.84%
|
8.40
|
| General And Administrative Expense |
|
5.77
-3.08%
|
5.95
-16.78%
|
7.15
-14.84%
|
8.40
|
| Other Gand A |
|
5.77
-3.08%
|
5.95
-16.78%
|
7.15
-14.84%
|
8.40
|
| Other Operating Expenses |
|
-1.28
-143.84%
|
-0.52
+43.22%
|
-0.92
+14.57%
|
-1.08
|
| Total Expenses |
|
17.92
+18.36%
|
15.14
-18.16%
|
18.50
+5.37%
|
17.55
|
| Operating Income |
|
-17.92
-18.36%
|
-15.14
+18.16%
|
-18.50
-5.37%
|
-17.55
|
| Total Operating Income As Reported |
|
-27.98
-78.66%
|
-15.66
+19.35%
|
-19.42
-4.21%
|
-18.63
|
| EBITDA |
|
-34.31
-111.90%
|
-16.19
+9.90%
|
-17.97
-3.09%
|
-17.43
|
| Normalized EBITDA |
|
-17.72
-16.60%
|
-15.20
+15.44%
|
-17.97
-3.09%
|
-17.43
|
| Reconciled Depreciation |
|
0.11
-78.65%
|
0.53
+3.50%
|
0.52
+424.05%
|
0.10
|
| EBIT |
|
-34.43
-105.81%
|
-16.73
+9.53%
|
-18.49
-5.46%
|
-17.53
|
| Total Unusual Items |
|
-16.59
-1567.17%
|
-1.00
|
0.00
|
0.00
|
| Total Unusual Items Excluding Goodwill |
|
-16.59
-1567.17%
|
-1.00
|
0.00
|
0.00
|
| Special Income Charges |
|
-7.20
-1440732.00%
|
0.00
|
0.00
|
0.00
|
| Restructuring And Mergern Acquisition |
|
7.20
|
0.00
|
—
|
—
|
| Net Income |
|
-34.66
-106.87%
|
-16.75
+9.66%
|
-18.55
-5.59%
|
-17.56
|
| Pretax Income |
|
-34.44
-105.52%
|
-16.75
+9.66%
|
-18.55
-5.59%
|
-17.56
|
| Net Non Operating Interest Income Expense |
|
0.07
+111.65%
|
-0.62
-1131.05%
|
-0.05
-337.23%
|
-0.01
|
| Interest Expense Non Operating |
|
0.01
-75.33%
|
0.03
-52.03%
|
0.06
+74.76%
|
0.03
|
| Net Interest Income |
|
0.07
+111.65%
|
-0.62
-1131.05%
|
-0.05
-337.23%
|
-0.01
|
| Interest Expense |
|
0.01
-75.33%
|
0.03
-52.03%
|
0.06
+74.76%
|
0.03
|
| Interest Income Non Operating |
|
0.08
+11478.65%
|
0.00
-87.06%
|
0.01
-74.11%
|
0.02
|
| Interest Income |
|
0.08
+11478.65%
|
0.00
-87.06%
|
0.01
-74.11%
|
0.02
|
| Other Income Expense |
|
-16.59
-1567.17%
|
-1.00
|
—
|
—
|
| Gain On Sale Of Security |
|
-9.39
-842.94%
|
-1.00
|
—
|
—
|
| Tax Provision |
|
0.23
|
0.00
|
—
|
—
|
| Tax Rate For Calcs |
|
0.00
|
0.00
|
0.00
|
0.00
|
| Tax Effect Of Unusual Items |
|
-3.48
|
0.00
|
0.00
|
0.00
|
| Net Income Including Noncontrolling Interests |
|
-34.66
-106.87%
|
-16.75
+9.66%
|
-18.55
-5.59%
|
-17.56
|
| Net Income From Continuing Operation Net Minority Interest |
|
-34.66
-106.87%
|
-16.75
+9.66%
|
-18.55
-5.59%
|
-17.56
|
| Net Income From Continuing And Discontinued Operation |
|
-34.66
-106.87%
|
-16.75
+9.66%
|
-18.55
-5.59%
|
-17.56
|
| Net Income Continuous Operations |
|
-34.66
-106.87%
|
-16.75
+9.66%
|
-18.55
-5.59%
|
-17.56
|
| Normalized Income |
|
-21.55
-36.76%
|
-15.76
+15.02%
|
-18.55
-5.59%
|
-17.56
|
| Net Income Common Stockholders |
|
-36.27
-116.09%
|
-16.79
+9.49%
|
-18.55
-5.59%
|
-17.56
|
| Otherunder Preferred Stock Dividend |
|
0.00
-100.00%
|
0.03
|
0.00
|
—
|
| Diluted EPS |
|
—
|
-1,336.63
+95.11%
|
-27,313.84
+97.36%
|
-1,033,233.41
|
| Basic EPS |
|
—
|
-1,336.63
+95.11%
|
-27,313.84
+97.36%
|
-1,033,233.41
|
| Basic Average Shares |
|
—
|
0.01
+1749.48%
|
0.00
+3894.12%
|
0.00
|
| Diluted Average Shares |
|
—
|
0.01
+1749.48%
|
0.00
+3894.12%
|
0.00
|
| Diluted NI Availto Com Stockholders |
|
-36.27
-116.09%
|
-16.79
+9.49%
|
-18.55
-5.59%
|
-17.56
|
| Gain On Sale Of PPE |
|
0.00
-100.00%
|
0.00
|
0.00
|
0.00
|
| Preferred Stock Dividends |
|
1.61
|
—
|
—
|
—
|
| Total Other Finance Cost |
|
—
|
0.60
|
—
|
—
|
| Line Item | Trend | 2023-12-31 |
|---|---|---|
| Total Assets |
|
5.17
|
| Current Assets |
|
4.46
|
| Cash Cash Equivalents And Short Term Investments |
|
2.77
|
| Cash And Cash Equivalents |
|
2.77
|
| Cash Financial |
|
2.77
|
| Receivables |
|
0.00
|
| Other Receivables |
|
—
|
| Prepaid Assets |
|
0.54
|
| Other Current Assets |
|
1.15
|
| Total Non Current Assets |
|
0.71
|
| Net PPE |
|
0.60
|
| Gross PPE |
|
0.87
|
| Accumulated Depreciation |
|
-0.26
|
| Machinery Furniture Equipment |
|
0.38
|
| Other Properties |
|
0.48
|
| Goodwill And Other Intangible Assets |
|
—
|
| Goodwill |
|
—
|
| Other Intangible Assets |
|
—
|
| Non Current Deferred Assets |
|
—
|
| Non Current Prepaid Assets |
|
0.11
|
| Total Liabilities Net Minority Interest |
|
3.53
|
| Current Liabilities |
|
3.49
|
| Payables And Accrued Expenses |
|
3.05
|
| Current Accrued Expenses |
|
3.05
|
| Current Debt And Capital Lease Obligation |
|
0.41
|
| Current Capital Lease Obligation |
|
0.41
|
| Current Deferred Liabilities |
|
0.03
|
| Current Deferred Revenue |
|
0.03
|
| Total Non Current Liabilities Net Minority Interest |
|
0.04
|
| Long Term Debt And Capital Lease Obligation |
|
0.04
|
| Long Term Capital Lease Obligation |
|
0.04
|
| Non Current Deferred Liabilities |
|
—
|
| Non Current Deferred Taxes Liabilities |
|
—
|
| Other Non Current Liabilities |
|
—
|
| Preferred Securities Outside Stock Equity |
|
—
|
| Stockholders Equity |
|
1.64
|
| Common Stock Equity |
|
1.64
|
| Capital Stock |
|
0.00
|
| Common Stock |
|
0.00
|
| Preferred Stock |
|
0.00
|
| Share Issued |
|
0.00
|
| Ordinary Shares Number |
|
0.00
|
| Treasury Shares Number |
|
0.00
|
| Additional Paid In Capital |
|
48.06
|
| Retained Earnings |
|
-46.42
|
| Total Equity Gross Minority Interest |
|
1.64
|
| Total Capitalization |
|
1.64
|
| Working Capital |
|
0.96
|
| Invested Capital |
|
1.64
|
| Total Debt |
|
0.45
|
| Capital Lease Obligations |
|
0.45
|
| Net Tangible Assets |
|
1.64
|
| Tangible Book Value |
|
1.64
|
| Derivative Product Liabilities |
|
0.00
|
| Duefrom Related Parties Current |
|
—
|
| Dueto Related Parties Current |
|
—
|
| Non Current Accrued Expenses |
|
—
|
| Preferred Stock Equity |
|
—
|
| Line Item | Trend | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|---|
| Operating Cash Flow |
|
-19.52
-46.34%
|
-13.34
+26.22%
|
-18.07
-14.67%
|
-15.76
|
| Cash Flow From Continuing Operating Activities |
|
-19.52
-46.34%
|
-13.34
+26.22%
|
-18.07
-14.67%
|
-15.76
|
| Net Income From Continuing Operations |
|
-34.66
-106.87%
|
-16.75
+9.66%
|
-18.55
-5.59%
|
-17.56
|
| Depreciation Amortization Depletion |
|
0.11
-78.65%
|
0.53
+3.50%
|
0.52
+424.05%
|
0.10
|
| Depreciation |
|
0.11
-78.65%
|
0.53
+3.50%
|
0.52
+424.05%
|
0.10
|
| Depreciation And Amortization |
|
0.11
-78.65%
|
0.53
+3.50%
|
0.52
+424.05%
|
0.10
|
| Other Non Cash Items |
|
5.25
|
—
|
—
|
—
|
| Stock Based Compensation |
|
0.49
-71.45%
|
1.70
+63.95%
|
1.04
+162.29%
|
0.40
|
| Operating Gains Losses |
|
9.28
+504.13%
|
1.54
|
—
|
—
|
| Gain Loss On Investment Securities |
|
9.28
+504.13%
|
1.54
|
—
|
—
|
| Gain Loss On Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Change In Working Capital |
|
0.02
+104.43%
|
-0.35
+67.52%
|
-1.08
-182.69%
|
1.31
|
| Change In Receivables |
|
-0.95
|
0.00
-100.00%
|
0.36
+200.00%
|
-0.36
|
| Change In Prepaid Assets |
|
0.48
+17.68%
|
0.41
+11.76%
|
0.36
+351.25%
|
-0.14
|
| Change In Payables And Accrued Expense |
|
0.22
+163.11%
|
-0.34
+73.53%
|
-1.30
-170.29%
|
1.84
|
| Change In Accrued Expense |
|
—
|
—
|
—
|
0.00
|
| Change In Payable |
|
—
|
—
|
—
|
1.84
|
| Change In Account Payable |
|
—
|
—
|
—
|
1.84
|
| Change In Other Working Capital |
|
0.20
+12268.59%
|
-0.00
-106.09%
|
0.03
+188.63%
|
-0.03
|
| Change In Other Current Assets |
|
0.11
|
0.00
+100.00%
|
-0.11
|
0.00
|
| Change In Other Current Liabilities |
|
-0.04
+90.71%
|
-0.41
+2.85%
|
-0.42
|
0.00
|
| Investing Cash Flow |
|
-0.00
+79.61%
|
-0.02
+38.89%
|
-0.04
+64.72%
|
-0.10
|
| Cash Flow From Continuing Investing Activities |
|
-0.00
+79.61%
|
-0.02
+38.89%
|
-0.04
+64.72%
|
-0.10
|
| Net PPE Purchase And Sale |
|
-0.01
+69.39%
|
-0.02
+38.89%
|
-0.04
+64.72%
|
-0.10
|
| Purchase Of PPE |
|
-0.01
+69.39%
|
-0.02
+38.89%
|
-0.04
+64.72%
|
-0.10
|
| Sale Of PPE |
|
—
|
—
|
—
|
0.00
|
| Capital Expenditure |
|
-0.01
+69.39%
|
-0.02
+38.89%
|
-0.04
+64.72%
|
-0.10
|
| Net Business Purchase And Sale |
|
0.00
|
0.00
|
—
|
—
|
| Financing Cash Flow |
|
31.52
+92.20%
|
16.40
+3.09%
|
15.91
+265542.41%
|
0.01
|
| Cash Flow From Continuing Financing Activities |
|
31.52
+92.20%
|
16.40
+3.09%
|
15.91
+265542.41%
|
0.01
|
| Net Issuance Payments Of Debt |
|
—
|
—
|
—
|
—
|
| Issuance Of Debt |
|
—
|
—
|
—
|
—
|
| Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Long Term Debt Issuance |
|
—
|
—
|
—
|
—
|
| Net Common Stock Issuance |
|
8.85
-46.01%
|
16.40
+3.09%
|
15.91
|
0.00
|
| Proceeds From Stock Option Exercised |
|
—
|
—
|
0.00
-100.00%
|
0.01
|
| Net Other Financing Charges |
|
—
|
—
|
—
|
—
|
| Changes In Cash |
|
12.00
+294.37%
|
3.04
+238.29%
|
-2.20
+86.12%
|
-15.86
|
| Beginning Cash Position |
|
5.81
+109.97%
|
2.77
-44.30%
|
4.97
-76.14%
|
20.83
|
| End Cash Position |
|
17.81
+206.54%
|
5.81
+109.97%
|
2.77
-44.30%
|
4.97
|
| Free Cash Flow |
|
-19.52
-46.15%
|
-13.36
+26.24%
|
-18.11
-14.16%
|
-15.86
|
| Interest Paid Supplemental Data |
|
0.01
-60.91%
|
0.02
-49.40%
|
0.03
-11.46%
|
0.04
|
| Income Tax Paid Supplemental Data |
|
—
|
—
|
—
|
—
|
| Change In Interest Payable |
|
—
|
—
|
—
|
0.00
|
| Common Stock Issuance |
|
8.85
-46.01%
|
16.40
+3.09%
|
15.91
|
0.00
|
| Issuance Of Capital Stock |
|
31.52
+92.20%
|
16.40
+3.09%
|
15.91
|
0.00
|
| Net Preferred Stock Issuance |
|
22.67
|
0.00
|
—
|
—
|
| Preferred Stock Issuance |
|
22.67
|
0.00
|
—
|
—
|
| Sale Of Business |
|
0.00
|
0.00
|
—
|
—
|
SEC Filings
Recent 10-K, 10-Q, 8-K, and Form 4 (insider) filings.
- 10-Q2026-05-15 View
- 10-K2026-04-15 View
- 8-K2026-04-07 View
- 8-K2026-03-03 View
- 8-K2026-02-23 View
- 8-K2026-02-05 View
- 8-K2026-01-06 View
- 8-K2025-12-22 View
- 8-K2025-12-11 View
- 10-Q2025-11-14 View
- 8-K2025-10-27 View
- 8-K2025-10-14 View
- 8-K2025-10-08 View
- 8-K2025-10-03 View
- 8-K2025-09-02 View
- 10-Q2025-08-14 View
- 8-K2025-06-13 View
- 10-Q2025-05-14 View
- 8-K2025-05-07 View
- 8-K2025-05-05 View
Trades
| Date | User | Broker | Pattern | Type | Position Size | Entry Price | Trade P&L | Status |
|---|
Posts
| Published | Title | Author | Category |
|---|